All In Biotech

Drug Trial Radar · NCT03228667

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

QUILT-3.055: A Phase IIb, Multicohort, Open-Label Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors

Last checked: Nov 20, 2026Latest source record: Jan 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Dec 11, 2018

Primary completion

Aug 31, 2029

Study completion Dec 31, 2030

Sponsor

Lead sponsor
ImmunityBio, Inc.Industry
Sponsor type
Industry
First posted
Jul 25, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

QUILT-3.055 is a Phase 2b, open-label, multicohort study investigating combination immunotherapies in patients with advanced solid tumors who have previously been treated with PD-1/PD-L1 checkpoint inhibitors. The study aims to evaluate the safety and efficacy of NAI (nogapendekin alfa inbakicept) in combination with other agents like checkpoint inhibitors and cell therapies across various cancer types and treatment settings. The study includes multiple cohorts based on prior therapies and cancer types, with a focus on assessing overall response rate (ORR), overall survival (OS), and other measures of anti-tumor activity and immune response.

Conditions

  • Non-Small Cell Lung Cancer
  • Small Cell Lung Cancer
  • Urothelial Carcinoma
  • Head and Neck Squamous Cell Carcinoma
  • Merkel Cell Carcinoma
  • Melanoma
  • Renal Cell Carcinoma
  • Gastric Cancer
  • Cervical Cancer
  • Hepatocellular Carcinoma
  • Microsatellite Instability
  • Mismatch Repair Deficiency
  • Colorectal Cancer

Interventions

  • N-803 + PembrolizumabDrug

    Patients will receive 200 mg pembrolizumab as an intravenous infusion over 30 minutes every three weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks.

  • N-803 + NivolumabDrug

    Patients will receive 240 mg nivolumab as an intravenous infusion over 30 minutes every two weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks.

  • N-803 + AtezolizumabDrug

    Patients will receive 1200 mg atezolizumab as an intravenous infusion over 60 minutes every 3 weeks; if the first infusion is tolerated, subsequent infusions may be given over 30 minutes. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks.

  • N-803 + AvelumabDrug

    Patients will receive 800 mg avelumab as an intravenous infusion over 60 minutes every 2 weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks.

  • N-803 + DurvalumabDrug

    Patients will receive 10 mg/kg durvalumab as an intravenous infusion over 60 minutes every 2 weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks.

  • N-803 + Pembrolizumab + PD-L1 t-haNKDrug

    Patients will receive 200 mg pembrolizumab as an intravenous infusion over 30 minutes every three weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks. Patients will receive PD-L1 t-haNK administered IV over 30 minutes at \~2 x 10\^9 cells/dose weekly

  • N-803 + Nivolumab + PD-L1 t-haNKDrug

    Patients will receive 240 mg nivolumab as an intravenous infusion over 30 minutes every two weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks. Patients will receive PD-L1 t-haNK administered IV over 30 minutes at \~2 x 10\^9 cells/dose weekly

  • N-803 + Atezolizumab + PD-L1 t-haNKDrug

    Patients will receive 1200 mg atezolizumab as an intravenous infusion over 60 minutes every 3 weeks; if the first infusion is tolerated, subsequent infusions may be given over 30 minutes. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks. Patients will receive PD-L1 t-haNK administered IV over 30 minutes at \~2 x 10\^9 cells/dose weekly

  • N-803 + Avelumab + PD-L1 t-haNKDrug

    Patients will receive 800 mg avelumab as an intravenous infusion over 60 minutes every 2 weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks. Patients will receive PD-L1 t-haNK administered IV over 30 minutes at \~2 x 10\^9 cells/dose weekly

  • N-803 + Durvalumab + PD-L1 t-haNKDrug

    Patients will receive 10 mg/kg durvalumab as an intravenous infusion over 60 minutes every 2 weeks. Patients will receive 15 µg/kg N-803 administered by subcutaneous injection every three weeks. Patients will receive PD-L1 t-haNK administered IV over 30 minutes at \~2 x 10\^9 cells/dose weekly

  • N-803 + Docetaxel + PembrolizumabDrug

    The study employs a 6-week cycle combination of: N-803 (1.2 mg flat dose SC), docetaxel (75 mg/m² IV - first 2 cycles only), and pembrolizumab (200 mg IV).

  • N-803 + Docetaxel + NivolumabDrug

    The study employs a 6-week cycle combination of:N-803 (1.2 mg flat dose SC), docetaxel (75 mg/m² IV - first 2 cycles only), and nivolumab (240 mg IV). Nivolumab dosing may be increased to 480mg every four weeks as per the investigator's discretion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ORR, defined as Investigator-assessed CR + PR per RECIST v1.1.Time frame: Evaluated from the first dose of study drug and repeated at each scheduled disease-assessment visit for up to 24 months (or until progression/death), with the time-to-response summarized using Kaplan-Meier methods
  2. Prolongation of OS with NAI therapy by ALC response, where: - OS is defined as the time from first study drug administration to death resulting from any cause. - ALC response is defined as achievement or maintenance of an on-treatment ALC ≥ 1,000 cells/μTime frame: Measured from the date of the first study-drug administration to the date of death (any cause) and followed for up to 24 months after the last dose (or until death), allowing the correlation with on-treatment ALC changes

Locations

35 sites in 1 country. Site status is shown where the registry gives one.

  • Alaska Clinical Research Center

    Anchorage, Alaska

  • Genesis Cancer Center

    Hot Springs, Arkansas

  • Chan Soon-Shiong Institute for Medicine

    El Segundo, California

  • MemorialCare Health System

    Fountain Valley, California

  • Glendale Adventist Medical Center

    Glendale, California

  • University of Southern California Norris Comprehensive Cancer Center

    Los Angeles, California

  • Desert Hematology Oncology Medical Group, Inc.

    Rancho Mirage, California

  • Memorial Healthcare System

    Hollywood, Florida

  • Miami Cancer Institute (Baptist Health South Florida)

    Miami, Florida

  • University of Miami

    Miami, Florida

  • Horizon Oncology Associates

    Lafayette, Indiana

  • University of Iowa Holden Comprehensive Cancer Center

    Iowa City, Iowa

  • Baptist Health - Lexington

    Lexington, Kentucky

  • Baptist Health- Louisville

    Louisville, Kentucky

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Henry Ford Hospital

    Detroit, Michigan

  • University of Minnesota - Masonic Cancer Center

    Minneapolis, Minnesota

  • Mercy Research Joplin

    Joplin, Missouri

  • Mercy Clinic Cancer & Hematology - Chub O'Reilly Cancer Center

    Springfield, Missouri

  • Washington University School of Medicine

    St Louis, Missouri

  • St. Vincent Frontier Cancer Center (SCL)

    Billings, Montana

  • Dartmouth-Hitchcock Medical Center

    Lebanon, New Hampshire

  • Roswell Park Cancer Institute

    Buffalo, New York

  • University of Rochester

    Rochester, New York

  • Cleveland Clinic - Main Site

    Cleveland, Ohio

  • Mercy Clinic Oklahoma City

    Oklahoma City, Oklahoma

  • Providence Portland Medical Center

    Portland, Oregon

  • Gettysburg/Hanover Cancer Centers

    Gettysburg, Pennsylvania

  • Medical University of South Carolina

    Charleston, South Carolina

  • St. Francis Cancer Center/Bon Secours St. Francis Health System

    Greenville, South Carolina

  • Spartanburg Medical Center

    Spartanburg, South Carolina

  • Sanford Clinical Research

    Sioux Falls, South Dakota

  • University of Tennessee Medical Center

    Knoxville, Tennessee

  • Oncology Consultants of Houston

    Houston, Texas

  • Bon Secours Richmond

    Richmond, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.